ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1796

Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans

Nicole Leung1, Michael Toprover1, Charles Fang2, Michael Pillinger3 and Jay Pendse4, 1Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, 2Department of Surgery Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, Worcester, MA, 3NYU Grossman School of Medicine, New York, NY, 4Division of Endocrinology, New York University Grossman School of Medicine and Endocrinology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY

Meeting: ACR Convergence 2022

Keywords: Atherosclerosis, gout, Peripheral Vascular Disease, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is known about their risk for PVD. Using electronic medical record data from the national Veterans Health Administration (VHA) system, we examined associations between gout, PVD and PVD sequelae including lower extremity amputation (LEA). We used diabetes (DM), a well-established risk factor for PVD, as a positive comparator.

Methods: We collected deidentified data from all VHA patients nationally with an active medical record from 2014–2018. After identifying PVD prevalence among all patients, we selected a random sample of 20% for initial analysis to allow for later internal validation. We classified gout, DM, and PVD using ICD-10 diagnosis codes. CPT codes were used to identify amputations as a surrogate for severe PVD. Using a multinomial logistic regression approach, we modeled odds of PVD and LEA in our 20% sample cohort as functions of gout, DM, and characteristics including race, ethnicity, sex, age, region, BMI, serum urate (SU) and baseline creatinine.

Results: 7,161,715 records were reviewed. In the total population, PVD identified through diagnosis code was 2.2x more prevalent in those with gout alone, 3.2x more prevalent in those with DM without gout, and 4x more prevalent in those with gout+DM, than those with neither (controls) (Table 1). Amputations by CPT codes yielded similar findings: 2.5x more prevalent in gout alone, 4.2x in DM without gout, and 5.8x in gout+DM compared with controls. Among the 20% randomly sampled population, controls tended to be younger (median 65, IQR 47–75 years) with lower BMI (median 29, IQR 25–32 years), while those with gout+DM tended to be older (median 74, IQR 68–78 years) with higher BMI (median 33, IQR 29–37) than patients with either gout or DM alone (Table 2). Patients with gout+DM had the highest mean SU at 8.2 mg/dL (SD 1.8) compared to 7.3 (SD 1.6) in DM only, 7.0 (SD 1.8) in gout only and 6.0 (SD 1.4) in controls. Patients with gout alone had rates of amputations that were higher than controls (consistent with a prior report1), but lower than those with DM alone (Figure 1). Patients with gout+DM had the highest rates of amputations. After controlling for potential risk factors, those with gout were 1.7x (CI:1.68-1.82) more likely to have PVD. Patients with DM were 2.6x (CI: 2.53-2.63) more likely. Patients with gout+DM were 3.2x (CI: 3.0-3.4) more likely to have PVD.

Conclusion: In a national VA cohort, individuals with gout were at significantly greater risk for PVD and LEA than patients without gout, but at lesser risk than individuals with DM, even after adjustment for confounders. Individuals with gout+DM were at the highest risk for PVD and LEA, although the interaction did not appear to be synergistic. These data suggest that gout is an underrecognized risk factor for PVD and indicate the importance of assessing for PVD when caring for gout patients.

1Mikuls TR et al. Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System. JAMA Netw Open. 2022;5(1):e2142347.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: N. Leung, None; M. Toprover, Horizon Pharma; C. Fang, None; M. Pillinger, Horizon Therapeutics, Sobi, Fortress Bioscience, Hikma; J. Pendse, Qiagen.

To cite this abstract in AMA style:

Leung N, Toprover M, Fang C, Pillinger M, Pendse J. Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/peripheral-vascular-disease-and-sequelae-in-individuals-with-gout-diabetes-or-both-among-us-veterans/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peripheral-vascular-disease-and-sequelae-in-individuals-with-gout-diabetes-or-both-among-us-veterans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology